论文部分内容阅读
多发性骨髓瘤(MM)BMT后即使完全缓解,其复发率仍可高达50％。据报道采用α-干扰素(IFN)维持治疗可延长自体BMT受者的缓解时间,但对异基因BMT后IFN的作用尚有待评价,为此欧洲多发性骨髓瘤BMT小组进行了研究。 IFN维持治疗条件为:病人无疾病进展,中性粒细胞>1.5×10~9/L、血小板>75×10~9/L,GVHD为0或Ⅰ级。IFN治疗至少于BMT2个月后进行,开始剂量为1mU 3/W,4周后增至2mU 3/W,再4周后增至3mU 3/W,拟维持至少2年。若应用后中性白细胞降至1.0～1.5×10~9/L或血小板50～75×10~9/L,则IFN剂量减半;中性粒细胞<1.0×10~9/L、血小板<50×10~9/L,则
After complete remission after BMT, multiple myeloma (MM) can still have a recurrence rate as high as 50%. It has been reported that the use of alpha-interferon (IFN) maintenance therapy can prolong the remission time of autologous BMT recipients, but the effect of IFN on allogeneic BMT remains to be evaluated. For this reason, the BMT group of multiple myeloma in Europe studied. The IFN maintenance treatment conditions were: no progression of the disease, neutrophils> 1.5 × 10-9/L, platelets> 75 × 10-9/L, and GVHD 0 or I. Treatment with IFN was performed at least 2 months after BMT with a starting dose of 1 mU 3/W, increased to 2 mU 3/W after 4 weeks, and increased to 3 mU 3/W after 4 weeks, and was intended to be maintained for at least 2 years. If the application of neutrophils to 1.0 ~ 1.5 × 10 ~ 9 / L or platelets 50 ~ 75 × 10 ~ 9 / L, the IFN dose halved; neutrophils <1.0 × 10 ~ 9 / L, platelets < 50×10~9/L, then